Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

32.94
BRL
-0.42
(-1.26%)
-3.23EPS
48.90BMarket Cap
Feb 10Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
- -
- -
0.05
0.02
0.22
0.11
0.16
0.28
0.28
- -
0.76
0.4
0.39
Basic EPS, GAAP
-0.15
-0.2
-0.16
-0.06
-0.08
0.09
-0.1
-0.17
-0.2
-0.24
-0.62
- -
-0.64
-0.63
Free Cash Flow per Basic Share
-0.1
-0.15
-0.14
-0.05
-0.07
0.21
-0.13
0.18
-0.22
-0.38
-0.62
0.14
-0.25
-0.25
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.37
0.23
0.17
0.13
0.13
0.31
0.55
0.48
0.46
0.31
0.18
0.42
0.04
0.04
Tangible Book Value per Share
0.37
0.18
0.13
0.1
0.11
0.29
0.54
0.47
0.45
0.3
0.17
0.42
0.04
0.04
Basic Weighted Avg Shares
382
467
497
601
680
763
819
844
862
873
974
1,088
1,133
1,142
Sales/Revenue/Turnover
- -
- -
- -
31
16
169
88
138
243
241
4
829
451
451
Operating Margin (%)
-29,202.23
-25,124.08
-50,331.84
-117.79
-346.52
36.25
-105.87
-107.77
-73.39
-85.16
-16,927.06
11.86
-156.86
-156.86
Depreciation Expense
1
2
3
5
5
4
6
8
10
12
19
24
27
27
Net Income, GAAP
-59
-92
-82
-34
-54
68
-85
-141
-176
-205
-599
-2
-724
-724
Effective Tax Rate (%)
- -
- -
- -
- -
- -
0.26
- -
- -
- -
- -
- -
41.56
- -
- -
Profit Margin (%)
-33,502.97
-24,068.29
-51,614.64
-109.46
-337.32
40.27
-96.09
-101.85
-72.39
-85.27
-16,882.37
-0.2
-160.64
-160.64
Working Capital
143
87
65
49
66
168
282
238
266
311
592
755
978
978
LT Debt
1
1
3
2
2
- -
20
23
79
105
504
319
955
955
Total Equity
166
110
95
81
95
244
462
409
418
287
191
503
51
51
Return on Invested Capital (%)
- -
- -
- -
- -
- -
35.73
- -
- -
- -
- -
- -
7.22
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
39.8
- -
- -
- -
- -
- -
2.4
- -
- -
Return on Common Equity (%)
-60.43
-66.45
-79.44
-38.85
-61.45
39.94
-23.94
-32.36
-43.62
-61.29
-262.48
-0.5
-280.5
-280.5

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
48
45
45
LT Borrowings
842
824
839
LT Finance Leases
100
114
116
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,143
1,148
1,149
Market Capitalization
8,242
11,781
9,435

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,840
1,671
1,289
Cash, Cash Equivalents & STI
1,784
1,602
1,193
Accounts Receivable, Net
16
9
10
Inventories
- -
- -
9
Total Current Liabilities
295
283
311
Payables & Accruals
128
137
167
ST Debt
48
45
45
Deferred Revenue
109
95
92

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.79%
2.2%
-89.97%
Free Cash Flow
-131.27%
-95.4%
-280.99%
Net Income, GAAP
4,405.43%
8,887.3%
44,302.58%
Sales/Revenue/Turnover
4,383.17%
4,637.77%
-45.65%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4
- -
- -
- -
4
2025
3
543
28
256
829
2026
264
74
75
38
451

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.15
-0.12
-0.17
-0.17
-0.62
2025
-0.17
0.34
-0.15
-0.02
- -
2026
0.03
-0.11
-0.17
-0.38
-0.64

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Christopher Richard Anzalone
Full Time Employees
1,059
Sector
Health technology
Industry
Biotechnology
Address
177 East Colorado Boulevard Pasadena CA United States 91105
IPO Date
Dec 14, 1993
Business
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) develops RNA interference (RNAi) therapeutics that silence genes causing intractable diseases using its proprietary Targeted RNAi Molecule (TRiM™) platform; the company's pipeline includes approximately 20 investigational medicines in clinical development across cardiometabolic, pulmonary, liver, neuromuscular, central nervous system, and complement-mediated disease areas, featuring lead candidates such as plozasiran (ARO-APOC3) for severe hypertriglyceridemia and familial chylomicronemia syndrome, zodasiran (ARO-ANG3) for mixed dyslipidemia and homozygous familial hypercholesterolemia, fazirsiran (ARO-AAT) for alpha-1 antitrypsin deficiency-associated liver disease, ARO-C3 for complement-mediated diseases like IgA nephropathy, ARO-MUC5AC and ARO-RAGE for muco-obstructive and inflammatory lung diseases, ARO-HBV for hepatitis B, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and others targeting conditions including chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and metabolic dysfunction-associated steatohepatitis. Founded in 2003 and headquartered in Pasadena, California, with research and development facilities in Madison and Verona, Wisconsin, and San Diego, California, Arrowhead operates primarily in the United States while advancing partnered and wholly owned programs globally through collaborations with major pharmaceutical companies. Recent developments include a November 2024 global license and collaboration agreement with Sarepta Therapeutics covering multiple clinical and preclinical programs in rare genetic diseases of muscle, CNS, and lungs, providing Arrowhead with $500 million upfront cash, $325 million in equity investment, and potential milestones exceeding $2.7 billion, alongside a $200 million milestone payment from Sarepta in 2025 for progress in the Phase 1/2 study of ARO-DM1 (SRP-1003) for type 1 myotonic dystrophy; the company also maintains ongoing partnerships with GlaxoSmithKline, Takeda, Janssen, Amgen, Horizon Therapeutics, and others, reported FDA approval for its first product plozasiran (branded Redemplo) with a potential commercial launch in 2025 pending final review, and projects cash runway extension into 2028 supported by substantial collaboration revenue of $240.6 million for fiscal year 2024.

Company News

  • 94,000 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR Bought by ACT Capital Partners L.P.

  • Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2026 Earnings Call Transcript

  • Arrowhead Pharmaceuticals Q4 Earnings Call Highlights

  • Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results

  • Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences

  • Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates

  • Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates

  • Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity

  • Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

  • Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides

  • Reviewing DBV Technologies (NASDAQ:DBVT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR)

  • Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New Platform

  • Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript

  • Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study

  • Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

  • Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

  • Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Breaks Below 200 Day Moving Average – Here’s Why

  • Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher

  • Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

  • Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress